Because the central role of KRAS is mediated by diverse cellular processes that not only occur in cancer cells but also involve the TME, this versatility of KRAS effector pathways is destined to dictate diverse adaptions that can be undertaken under treatment pressure. The gene discussed is KRAS; the disease is cancer.